Novel Bruton's tyrosine kinase inhibitors currently in development

Novel Bruton's tyrosine kinase inhibitors currently in development

Osmond J D'Cruz,1 Fatih M Uckun1,21Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; 2Department of Pediatrics, University of Southern California, Los Angeles, CA, USAAbstract: Bruton's tyrosine kin...

Full description

Bibliographic Details
Main Authors: D'Cruz OJ, Uckun FM
Format: Article
Language:English
Published: Dove Medical Press 2013-03-01
Series:OncoTargets and Therapy
Online Access:http://www.dovepress.com/novel-bruton39s-tyrosine-kinase-inhibitors-currently-in-development-a12394
id doaj-0c8aa0267e0a452badfb741ba3dcc1e2
record_format Article
spelling doaj-0c8aa0267e0a452badfb741ba3dcc1e22020-11-24T22:51:35ZengDove Medical PressOncoTargets and Therapy1178-69302013-03-012013default161176Novel Bruton's tyrosine kinase inhibitors currently in developmentD'Cruz OJUckun FMOsmond J D'Cruz,1 Fatih M Uckun1,21Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; 2Department of Pediatrics, University of Southern California, Los Angeles, CA, USAAbstract: Bruton's tyrosine kinase (Btk) is intimately involved in multiple signal-transduction pathways regulating survival, activation, proliferation, and differentiation of B-lineage lymphoid cells. Btk is overexpressed and constitutively active in several B-lineage lymphoid malignancies. Btk has emerged as a new antiapoptotic molecular target for treatment of B-lineage leukemias and lymphomas. Preclinical and early clinical results indicate that Btk inhibitors may be useful in the treatment of leukemias and lymphomas.Keywords: tyrosine kinase, personalized therapy, kinase inhibitors, Btk, leukemia, lymphomahttp://www.dovepress.com/novel-bruton39s-tyrosine-kinase-inhibitors-currently-in-development-a12394
collection DOAJ
language English
format Article
sources DOAJ
author D'Cruz OJ
Uckun FM
spellingShingle D'Cruz OJ
Uckun FM
Novel Bruton's tyrosine kinase inhibitors currently in development
OncoTargets and Therapy
author_facet D'Cruz OJ
Uckun FM
author_sort D'Cruz OJ
title Novel Bruton's tyrosine kinase inhibitors currently in development
title_short Novel Bruton's tyrosine kinase inhibitors currently in development
title_full Novel Bruton's tyrosine kinase inhibitors currently in development
title_fullStr Novel Bruton's tyrosine kinase inhibitors currently in development
title_full_unstemmed Novel Bruton's tyrosine kinase inhibitors currently in development
title_sort novel bruton's tyrosine kinase inhibitors currently in development
publisher Dove Medical Press
series OncoTargets and Therapy
issn 1178-6930
publishDate 2013-03-01
description Osmond J D'Cruz,1 Fatih M Uckun1,21Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; 2Department of Pediatrics, University of Southern California, Los Angeles, CA, USAAbstract: Bruton's tyrosine kinase (Btk) is intimately involved in multiple signal-transduction pathways regulating survival, activation, proliferation, and differentiation of B-lineage lymphoid cells. Btk is overexpressed and constitutively active in several B-lineage lymphoid malignancies. Btk has emerged as a new antiapoptotic molecular target for treatment of B-lineage leukemias and lymphomas. Preclinical and early clinical results indicate that Btk inhibitors may be useful in the treatment of leukemias and lymphomas.Keywords: tyrosine kinase, personalized therapy, kinase inhibitors, Btk, leukemia, lymphoma
url http://www.dovepress.com/novel-bruton39s-tyrosine-kinase-inhibitors-currently-in-development-a12394
work_keys_str_mv AT damp39cruzoj novelbrutonamp39styrosinekinaseinhibitorscurrentlyindevelopment
AT uckunfm novelbrutonamp39styrosinekinaseinhibitorscurrentlyindevelopment
_version_ 1725668983750787072

Similar Items